News Focus
News Focus
icon url

dstock07734

02/03/25 11:07 AM

#747209 RE: ilovetech #747183

ILT,

BNTX has terminated a bunch of trials too. You see what they were doing? They enrolled patients and ran the trials. If the results were not good, they just terminated them with no need releasing any PR.

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma
ClinicalTrials.gov ID NCT06069778
https://clinicaltrials.gov/study/NCT06069778

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
https://clinicaltrials.gov/study/NCT04683939

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)
https://clinicaltrials.gov/study/NCT04382898

BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors
https://clinicaltrials.gov/study/NCT04455620


Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy (OLIVIA)
https://clinicaltrials.gov/study/NCT04163094


Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411
https://clinicaltrials.gov/study/NCT04101357


A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
https://clinicaltrials.gov/study/NCT03871348


Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
https://clinicaltrials.gov/study/NCT02672917
icon url

Margin Buu

02/03/25 12:30 PM

#747229 RE: ilovetech #747183

I second this. 🎯
icon url

exwannabe

02/03/25 12:38 PM

#747232 RE: ilovetech #747183

Yup, it is always corruption, "captured" agencies and the like.

It is always the umpires fault when my team loses. Never the teams fault.